Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Signs Contract with Blue Shield of California

NEW YORK (GenomeWeb News) – Agendia today said that it has signed a contract with Blue Shield of California, making it an in-network provider.

The deal, Agendia said, opens the way for other Blue Cross affiliates nationwide to cover Agendia's tests including its MammaPrint. Other payors, including Medicare, Humana, and United Healthcare, also have coverage policies for MammaPrint, and the company has contracts with Palmetto, Humana, Coventry and other national preferred provider organization plans.

MammaPrint, Agendia's lead product, is a gene expression signature assay for determining which patients with breast cancer may be at risk of metastases. The test can help guide treatment decisions.

The Dutch molecular diagnostics firm filed for an initial public offering in Europe in June but shelved it two weeks later citing adverse market conditions. Most recently David Macdonald replaced Bernhard Sixt as Agendia's CEO.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.